MedTrace Logo

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

NCT01622543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2023-08-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.

Conditions

Interventions

DRUG

Folfox plus Bevacizumab and reolysin

FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter

DRUG

Folfox plus Bevacizumab

FOLFOX6/bevacizumab given every 14 days.

Sponsors & Collaborators

Principal Investigators

  • Derek Jonker · Ottawa Health Research Institute - General Division

  • Patricia Tang · Tom Baker Cancer Centre, Calgary, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-26
Primary Completion
2017-01-18
Completion
2018-09-12

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01622543 on ClinicalTrials.gov